Clinical trials: Pharyngeal Cancer
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
This study is a multicenter, randomized, controlled phase III clinical trial aiming to investigate the efficacy and safety of Becotatug Vedotin induction therapy followed by concurrent chemoradiotherapy (CCRT) combined with…
- Trial name
- NCT07459296
- Testing
- Becotatug Vedotin, Sintilimab, Cisplatin
- Where
- China
- Volunteers
- 266 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Cancer, EBV Infections
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
To determine the safety of the combination of CD45 monoclonal antibody (Mab) followed by intravenous injection of EBV specific CTL in patients with nasopharyngeal cancer.
- Trial name
- CLANC (NCT00078546)
- Testing
- EBV specific CTL Infusion, Anti CD45 monoclonal antibody
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Baylor College of Medicine
Radiation-induced Oropharyngeal Mucositis, Swallowing-induced Breakthrough Pain
A Mucosal Contouring Method Based on Swallowing-induced Breakthrough Pain for Radiation-induced Oropharyngeal Mucositis
The performance of the predictive models for severe oropharyngeal mucositis established using current oral mucosal contouring method was unsatisfactory in nasopharyngeal carcinoma (NPC).
- Trial name
- NCT06287788
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Oral Cancer, Chatbot
Enhancing Oral Cancer Awareness
To evaluate the impact of AI-powered chatbot interactions versus traditional educational handouts on increasing participants' knowledge of oral cancer and its prevention
- Conditions
- Oral Cancer, Chatbot, Patient Education, Prevention
- Trial name
- NCT06682494
- Testing
- Traditional Education, AI-powered Chatbox
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Nasopharyngeal Carcinoma
Reduced Target Delineation and Radiation Doses Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
To determine the efficacy and safety of sequential chemoradiotherapy with regimen of docetaxel, cisplatin and fluorouracil and reduced target delineation and radiation doses IMRT for patients with locoregionally advanced…
- Trial name
- NCT03389295
- Testing
- Reduced Target Delineation and Radiation Doses
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Xiayun He, MD
Swallowing Function
Detecting the Changes of Swallowing Function in Oral Cancer Patients
The evidence of swallowing changes in oral cancer patients is still limited. This study aimed to investigated the swallowing changes in these patients by using the videofluoroscopy (VFSS) and high resolution impedance manometry…
- Trial name
- NCT04862637
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction…
- Trial name
- NCT04456322
- Testing
- RT plus Nimotuzumab, RT plus Cisplatin
- Where
- China
- Volunteers
- 381 people
- Sponsor
- Sun Yat-sen University
Laryngeal Cancer, Hypopharynx Cancer
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and…
- Trial name
- NCT06611137
- Testing
- SBRT+Toripalimab Plus Docetaxel and Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Oropharyngeal Cancer
Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy
The purpose of this study is to investigate the role of the immune system in the response of squamous cell cancers of the head and neck to treatment that includes radiation therapy.
- Conditions
- Head and Neck Cancer, Oropharyngeal Cancer, Human Papillomavirus, Squamous Cell Cancer
- Trial name
- NCT01358097
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Head and Neck Cancer, Dysphagia
Training Swallowing Initiation During Expiration
Head and neck cancers have escalated to epidemic levels in the United States, and survivors are suffering from life-long, devastating swallowing disorders with limited therapeutic options.
- Conditions
- Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Squamous Cell Carcinoma
- Trial name
- NCT05278039
- Testing
- Respiratory-Swallow Phase Training, Swallow Practice
- Where
- 2 sites in United States
- Volunteers
- 88 people
- Sponsor
- Northwestern University
Nasopharyngeal Neoplasms, Elderly
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
This prospective, multicenter, single-arm, open-label phase II clinical study aimed to investigate the efficacy and safety of intensity-modulated radiotherapy combined with lobaplatin-based concurrent chemotherapy in the…
- Conditions
- Nasopharyngeal Neoplasms, Elderly, Chemotherapy
- Trial name
- NCT06688175
- Testing
- IMRT combined with lobaplatin-based concurrent chemotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+…
- Trial name
- HexAgon-HN (NCT06295731)
- Testing
- INBRX-106, Pembrolizumab
- Where
- 89 sites in United States, Australia and 11 more
- Volunteers
- 450 people
- Sponsor
- Inhibrx Biosciences, Inc
Nasopharyngeal Carcinoma
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in…
- Trial name
- NCT06323239
- Testing
- SBRT, Low-dose Radiotherapy (LDRT), Toripalimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancer, Epstein-Barr Virus Infections
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
The purpose of this study is to evaluate the efficacy (clinical benefit rate) of MVA EBNA1/LMP2 vaccine in patients with persistent, recurrent or metastatic nasopharyngeal carcinoma, and its impact on disease progression.
- Trial name
- NCT01094405
- Testing
- Recombinant Epstein-Barr Virus (EBV) Vaccine
- Where
- Hong Kong
- Volunteers
- 25 people
- Sponsor
- Chinese University of Hong Kong
Head and Neck Cancer
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiosensitizing drugs, such as cytochlor and tetrahydrouridine, may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00077051
- Testing
- cisplatin, cytochlor, tetrahydrouridine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Larynx, Lip, Oral Cavity and Pharynx
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
This pilot clinical trial studies the side effects of nivolumab, ipilimumab and radiation therapy in treating patients with stage IVA-B head and neck cancer.
- Trial name
- NCT03162731
- Testing
- Nivolumab, Ipilimumab, Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
HPV, Oropharynx Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC.
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
- Trial name
- NCT05307939
- Testing
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dysphagia
Pharyngocise Dose Response Study
In this study supported by an American Cancer Society grant, the investigators are evaluating two levels of swallowing exercise intensity on the maintenance of swallowing muscles and their function in Head/Neck cancer patients…
- Trial name
- NCT01279837
- Testing
- Pharyngocise
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Florida
Nasopharyngeal Carcinoma (NPC)
Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China
Background: Nasopharyngeal carcinoma (NPC) is a malignancy with marked geographic variation, with over 80% of global cases found in Southeast and East Asia.
- Trial name
- NCT07088861
- Volunteers
- 1,401 people
- Sponsor
- Lirong Wu
Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma
RATIONALE: Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT01064921
- Testing
- vorinostat, cisplatin, radiation therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.